{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:44:02Z","timestamp":1792640642051,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40259-023-00603-8","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:46:54Z","timestamp":1686070014000},"page":"699-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of Reported Adverse Events After Interchanging Between TNF-\u03b1 Inhibitor Biosimilars in the WHO Pharmacovigilance Database"],"prefix":"10.1007","volume":"37","author":[{"given":"Orhon","family":"Pauline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bernardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hlavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Roustit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-8573","authenticated-orcid":false,"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"603_CR1","unstructured":"European Medicines Agency. Biosimilar medicines: overview. 2018. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview. Accessed 2 Dec 2022."},{"key":"603_CR2","unstructured":"Biosimilar product information. FDA; 2022. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 2 Dec 2022"},{"key":"603_CR3","doi-asserted-by":"publisher","first-page":"19569","DOI":"10.1038\/s41598-022-24050-7","volume":"12","author":"H Jourdain","year":"2022","unstructured":"Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. Sci Rep. 2022;12:19569.","journal-title":"Sci Rep"},{"key":"603_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s12325-021-01688-9","volume":"38","author":"A Afzali","year":"2021","unstructured":"Afzali A, Furtner D, Melsheimer R, Molloy PJ. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38:2077\u201393.","journal-title":"Adv Ther"},{"key":"603_CR5","unstructured":"Biosimilars in the EU: information guide for healthcare professionals.\nhttps:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcareprofessionals_en.pdf Accessed 2 Dec 2022."},{"key":"603_CR6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"E Mysler","year":"2021","unstructured":"Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81:1859\u201379.","journal-title":"Drugs"},{"key":"603_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225867","volume":"15","author":"T Salam","year":"2020","unstructured":"Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, et al. Physicians\u2019 perspectives regarding non-medical switching of prescription medications: results of an internet e-survey. PLoS ONE. 2020;15: e0225867.","journal-title":"PLoS ONE"},{"key":"603_CR8","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","volume":"24","author":"H Schellekens","year":"2002","unstructured":"Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720\u201340 (discussion 1719).","journal-title":"Clin Ther"},{"key":"603_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","volume":"75","author":"MB Ruiz-Arg\u00fcello","year":"2016","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Mart\u00ednez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693\u20136.","journal-title":"Ann Rheum Dis"},{"key":"603_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","volume":"50","author":"A Lauret","year":"2020","unstructured":"Lauret A, Molt\u00f3 A, Abitbol V, Gutermann L, Conort O, Chast F, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020;50:1449\u201356.","journal-title":"Semin Arthritis Rheum"},{"key":"603_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/apt.14453","volume":"47","author":"EMH Schmitz","year":"2018","unstructured":"Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47:356\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"603_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"J Avouac","year":"2018","unstructured":"Avouac J, Molt\u00f3 A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018;47:741\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"603_CR13","doi-asserted-by":"crossref","unstructured":"Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677\u201383 (Expert Opin Biol Ther. 2016;16:1311\u20132).","DOI":"10.1080\/14712598.2016.1198765"},{"key":"603_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet M-E, Bannwarth B, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Jt Bone Spine. 2018;85:561\u20137.","journal-title":"Jt Bone Spine"},{"key":"603_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clinthera.2018.11.002","volume":"41","author":"G Bakalos","year":"2019","unstructured":"Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41:155-73.e13.","journal-title":"Clin Ther"},{"key":"603_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"603_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"603_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32:397\u2013404.","journal-title":"BioDrugs"},{"key":"603_CR19","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2023. https:\/\/www.whocc.no\/filearchive\/publications\/2023_guidelines_web.pdf. Accessed 2 Dec 2022"},{"key":"603_CR20","doi-asserted-by":"publisher","unstructured":"Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a network-based signal detection tool: the COVID-19 Adversome in the FDA Adverse Event Reporting System. Front Pharmacol. 2021;12. https:\/\/doi.org\/10.3389\/fphar.2021.740707. Accessed 8 Dec 2022.","DOI":"10.3389\/fphar.2021.740707"},{"key":"603_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40259-022-00538-6","volume":"36","author":"JP Park","year":"2022","unstructured":"Park JP, Jung B, Park HK, Shin D, Jung JA, Ghil J, et al. Interchangeability for biologics is a legal distinction in the USA, not a clinical one. BioDrugs. 2022;36:431\u20136.","journal-title":"BioDrugs"},{"key":"603_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382:554\u201361.","journal-title":"N Engl J Med"},{"key":"603_CR23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","volume":"78","author":"JP Howard","year":"2021","unstructured":"Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78:1210\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"603_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k714","volume":"360","author":"B Casassus","year":"2018","unstructured":"Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ. 2018;360: k714.","journal-title":"BMJ"},{"key":"603_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7:35\u201364.","journal-title":"Rheumatol Ther."},{"key":"603_CR26","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"603_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o2939","volume":"379","author":"SU Khan","year":"2022","unstructured":"Khan SU, Kleiman NS. Statin related muscle symptoms: is it time to move on. BMJ. 2022;379: o2939.","journal-title":"BMJ"},{"key":"603_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463\u201378.","journal-title":"Drugs"},{"key":"603_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022;36:625\u201337.","journal-title":"BioDrugs"},{"key":"603_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40259-022-00548-4","volume":"36","author":"K Dutt","year":"2022","unstructured":"Dutt K, Srinivasan A, Van Langenberg D. The nocebo effect in a non-medical switching program from originator to biosimilar infliximab in inflammatory bowel disease. BioDrugs. 2022;36:639\u201344.","journal-title":"BioDrugs"},{"key":"603_CR31","doi-asserted-by":"publisher","unstructured":"Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10. https:\/\/doi.org\/10.3389\/fphar.2019.01372. Accessed 22 Dec 2022.","DOI":"10.3389\/fphar.2019.01372"},{"key":"603_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/bs.irn.2018.07.016","volume":"139","author":"K Faasse","year":"2018","unstructured":"Faasse K, Martin LR. The power of labeling in nocebo effects. Int Rev Neurobiol. 2018;139:379\u2013406.","journal-title":"Int Rev Neurobiol"},{"key":"603_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s11096-019-00826-2","volume":"41","author":"K Svensberg","year":"2019","unstructured":"Svensberg K, Nordeng H, Gaffari S, Faasse K, Horne R, Lupattelli A. Perceived sensitivity to medicines: a study among chronic medicine users in Norway. Int J Clin Pharm. 2019;41:804\u201312.","journal-title":"Int J Clin Pharm"},{"key":"603_CR34","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1016\/S1470-2045(20)30485-X","volume":"21","author":"CL Bennett","year":"2020","unstructured":"Bennett CL, Schoen MW, Hoque S, Witherspoon BJ, Aboulafia DM, Hwang CS, et al. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020;21:e575\u201388.","journal-title":"Lancet Oncol"},{"key":"603_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001396","volume":"7","author":"J Petit","year":"2021","unstructured":"Petit J, Antignac M, Poilverd R-M, Baratto R, Darthout S, Desouches S, et al. Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar. RMD Open. 2021;7: e001396.","journal-title":"RMD Open"},{"key":"603_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40259-022-00545-7","volume":"36","author":"DJ Rupert","year":"2022","unstructured":"Rupert DJ, Jordan AM, Ziemian MA, Brown RM, Fleming NS, Lefebvre RC. Understanding US physician and pharmacist attitudes toward biosimilar products: a qualitative study. BioDrugs. 2022;36:645\u201355.","journal-title":"BioDrugs"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00603-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:13:56Z","timestamp":1692195236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00603-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00603-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"1 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Orhon Pauline, Marion Robert, Claire Bernardeau, Alex Hlavaty, Michele Fusaroli, Matthieu Roustit, Jean-Luc Cracowski, and Charles Khouria have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are made available by the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The codes used during the current study are made available by the corresponding author on request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CK: conceptualization, methodology, investigation, formal analysis, writing (original draft), writing (review and editing); OP: investigation, formal analysis, writing (original draft); AH: formal analysis; MR, CB, MF, MR, J-LC; writing (review and editing). All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}